Versatility of mesenchymal stem cell-derived extracellular vesicles in tissue repair and regenerative applications
Mesenchymal stem/stromal cells (MSCs) are multipotent somatic cells that have been widely explored in the field of regenerative medicine. MSCs possess the ability to secrete soluble factors as well as lipid bound extracellular vesicles (EVs). MSCs have gained increased interest and attention as a re...
Gespeichert in:
Veröffentlicht in: | Biochimie 2023-04, Vol.207, p.33-48 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 48 |
---|---|
container_issue | |
container_start_page | 33 |
container_title | Biochimie |
container_volume | 207 |
creator | Williams, Taylor Salmanian, Ghazaleh Burns, Morgan Maldonado, Vitali Smith, Emma Porter, Ryan M. Song, Young Hye Samsonraj, Rebekah Margaret |
description | Mesenchymal stem/stromal cells (MSCs) are multipotent somatic cells that have been widely explored in the field of regenerative medicine. MSCs possess the ability to secrete soluble factors as well as lipid bound extracellular vesicles (EVs). MSCs have gained increased interest and attention as a result of their therapeutic properties, which are thought to be attributed to their secretome. However, while the use of MSCs as whole cells pose heterogeneity concerns and survival issues post-transplantation, such limitations are absent in cell-free EV-based treatments. EVs derived from MSCs are promising therapeutic agents for a range of clinical conditions and disorders owing to their immunomodulatory, pro-regenerative, anti-inflammatory, and antifibrotic activity. Recent successes with preclinical studies using EVs for repair and regeneration of damaged tissues such as cardiac tissue, lung, liver, pancreas, bone, skin, cornea, and blood diseases are discussed in this review. We also discuss delivery strategies of EVs using biomaterials as delivery vehicles through systemic or local administration. Despite its effectiveness in preclinical investigations, the application of MSC-EV in clinical settings will necessitate careful consideration surrounding issues such as: i) scalability and isolation, ii) biodistribution, iii) targeting specific tissues, iv) quantification and characterization, and v) safety and efficacy of dosage. The future of EVs in regenerative medicine is promising yet still needs further investigation on enhancing the efficacy, scalability, and potency for clinical applications.
•MSC-derived EVs are promising therapeutic agents for several clinical conditions.•Complexity of MSC-EV cargo and effects of culture environments are discussed.•Challenges in MSC-EV manufacturing and possible solutions are addressed.•Biomanufacturing of MSC-EVs requires careful considerations of GMP-compliant processes. |
doi_str_mv | 10.1016/j.biochi.2022.11.011 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2740515760</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0300908422003078</els_id><sourcerecordid>2740515760</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-c03a167e69ce3bf8f85fe546b8bddfaa6b827f3943b5156beb00ccd916d965683</originalsourceid><addsrcrecordid>eNp9kEtr3TAQhUVpaG4e_6AULbuxM7JsWd4EQkiaQCCbtFshS-NGF7-qsS-5_z663LTLruYwnDOPj7GvAnIBQl1t8zZM7jXkBRRFLkQOQnxiG6GkzpTQ8jPbgATIGtDlKTsj2gJABUXzhZ1KVRa10mLD4i-MZJfQh2XPp44PSDi61_1ge04LDtxh32ceY9ih5_i2RHvorL2NfIcUXI_Ew8iXQLQijzjbELkdfZK_ccSYZu-Q23nug0t6GumCnXS2J7z8qOfs5_3dy-1D9vT84_H25ilzJeglcyCtUDWqxqFsO93pqsOqVK1uve-sTaKoO9mUsq1EpVpsAZzzjVC-UZXS8px9P86d4_RnRVrMEOhwvB1xWskUdQkpWStI1vJodXEiitiZOYbBxr0RYA60zdYcaZsDbSOESbRT7NvHhrUd0P8L_cWbDNdHA6Y_dwGjIRcSX_QholuMn8L_N7wDZNeVqA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2740515760</pqid></control><display><type>article</type><title>Versatility of mesenchymal stem cell-derived extracellular vesicles in tissue repair and regenerative applications</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Williams, Taylor ; Salmanian, Ghazaleh ; Burns, Morgan ; Maldonado, Vitali ; Smith, Emma ; Porter, Ryan M. ; Song, Young Hye ; Samsonraj, Rebekah Margaret</creator><creatorcontrib>Williams, Taylor ; Salmanian, Ghazaleh ; Burns, Morgan ; Maldonado, Vitali ; Smith, Emma ; Porter, Ryan M. ; Song, Young Hye ; Samsonraj, Rebekah Margaret</creatorcontrib><description>Mesenchymal stem/stromal cells (MSCs) are multipotent somatic cells that have been widely explored in the field of regenerative medicine. MSCs possess the ability to secrete soluble factors as well as lipid bound extracellular vesicles (EVs). MSCs have gained increased interest and attention as a result of their therapeutic properties, which are thought to be attributed to their secretome. However, while the use of MSCs as whole cells pose heterogeneity concerns and survival issues post-transplantation, such limitations are absent in cell-free EV-based treatments. EVs derived from MSCs are promising therapeutic agents for a range of clinical conditions and disorders owing to their immunomodulatory, pro-regenerative, anti-inflammatory, and antifibrotic activity. Recent successes with preclinical studies using EVs for repair and regeneration of damaged tissues such as cardiac tissue, lung, liver, pancreas, bone, skin, cornea, and blood diseases are discussed in this review. We also discuss delivery strategies of EVs using biomaterials as delivery vehicles through systemic or local administration. Despite its effectiveness in preclinical investigations, the application of MSC-EV in clinical settings will necessitate careful consideration surrounding issues such as: i) scalability and isolation, ii) biodistribution, iii) targeting specific tissues, iv) quantification and characterization, and v) safety and efficacy of dosage. The future of EVs in regenerative medicine is promising yet still needs further investigation on enhancing the efficacy, scalability, and potency for clinical applications.
•MSC-derived EVs are promising therapeutic agents for several clinical conditions.•Complexity of MSC-EV cargo and effects of culture environments are discussed.•Challenges in MSC-EV manufacturing and possible solutions are addressed.•Biomanufacturing of MSC-EVs requires careful considerations of GMP-compliant processes.</description><identifier>ISSN: 0300-9084</identifier><identifier>EISSN: 1638-6183</identifier><identifier>DOI: 10.1016/j.biochi.2022.11.011</identifier><identifier>PMID: 36427681</identifier><language>eng</language><publisher>France: Elsevier B.V</publisher><subject>Animals ; Biotechnology - methods ; Biotechnology - standards ; Biotechnology - trends ; Cellular therapies ; Clinical trials ; EVs ; Extracellular vesicles ; Extracellular Vesicles - classification ; Extracellular Vesicles - immunology ; Extracellular Vesicles - metabolism ; Humans ; Mesenchymal stem cells ; Mesoderm - cytology ; Regeneration ; Regenerative medicine ; Regenerative Medicine - methods ; Regenerative Medicine - standards ; Regenerative Medicine - trends ; Stem Cells - cytology ; Tissue repair</subject><ispartof>Biochimie, 2023-04, Vol.207, p.33-48</ispartof><rights>2022 The Authors</rights><rights>Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-c03a167e69ce3bf8f85fe546b8bddfaa6b827f3943b5156beb00ccd916d965683</citedby><cites>FETCH-LOGICAL-c408t-c03a167e69ce3bf8f85fe546b8bddfaa6b827f3943b5156beb00ccd916d965683</cites><orcidid>0000-0001-8804-8284</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biochi.2022.11.011$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36427681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Williams, Taylor</creatorcontrib><creatorcontrib>Salmanian, Ghazaleh</creatorcontrib><creatorcontrib>Burns, Morgan</creatorcontrib><creatorcontrib>Maldonado, Vitali</creatorcontrib><creatorcontrib>Smith, Emma</creatorcontrib><creatorcontrib>Porter, Ryan M.</creatorcontrib><creatorcontrib>Song, Young Hye</creatorcontrib><creatorcontrib>Samsonraj, Rebekah Margaret</creatorcontrib><title>Versatility of mesenchymal stem cell-derived extracellular vesicles in tissue repair and regenerative applications</title><title>Biochimie</title><addtitle>Biochimie</addtitle><description>Mesenchymal stem/stromal cells (MSCs) are multipotent somatic cells that have been widely explored in the field of regenerative medicine. MSCs possess the ability to secrete soluble factors as well as lipid bound extracellular vesicles (EVs). MSCs have gained increased interest and attention as a result of their therapeutic properties, which are thought to be attributed to their secretome. However, while the use of MSCs as whole cells pose heterogeneity concerns and survival issues post-transplantation, such limitations are absent in cell-free EV-based treatments. EVs derived from MSCs are promising therapeutic agents for a range of clinical conditions and disorders owing to their immunomodulatory, pro-regenerative, anti-inflammatory, and antifibrotic activity. Recent successes with preclinical studies using EVs for repair and regeneration of damaged tissues such as cardiac tissue, lung, liver, pancreas, bone, skin, cornea, and blood diseases are discussed in this review. We also discuss delivery strategies of EVs using biomaterials as delivery vehicles through systemic or local administration. Despite its effectiveness in preclinical investigations, the application of MSC-EV in clinical settings will necessitate careful consideration surrounding issues such as: i) scalability and isolation, ii) biodistribution, iii) targeting specific tissues, iv) quantification and characterization, and v) safety and efficacy of dosage. The future of EVs in regenerative medicine is promising yet still needs further investigation on enhancing the efficacy, scalability, and potency for clinical applications.
•MSC-derived EVs are promising therapeutic agents for several clinical conditions.•Complexity of MSC-EV cargo and effects of culture environments are discussed.•Challenges in MSC-EV manufacturing and possible solutions are addressed.•Biomanufacturing of MSC-EVs requires careful considerations of GMP-compliant processes.</description><subject>Animals</subject><subject>Biotechnology - methods</subject><subject>Biotechnology - standards</subject><subject>Biotechnology - trends</subject><subject>Cellular therapies</subject><subject>Clinical trials</subject><subject>EVs</subject><subject>Extracellular vesicles</subject><subject>Extracellular Vesicles - classification</subject><subject>Extracellular Vesicles - immunology</subject><subject>Extracellular Vesicles - metabolism</subject><subject>Humans</subject><subject>Mesenchymal stem cells</subject><subject>Mesoderm - cytology</subject><subject>Regeneration</subject><subject>Regenerative medicine</subject><subject>Regenerative Medicine - methods</subject><subject>Regenerative Medicine - standards</subject><subject>Regenerative Medicine - trends</subject><subject>Stem Cells - cytology</subject><subject>Tissue repair</subject><issn>0300-9084</issn><issn>1638-6183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtr3TAQhUVpaG4e_6AULbuxM7JsWd4EQkiaQCCbtFshS-NGF7-qsS-5_z663LTLruYwnDOPj7GvAnIBQl1t8zZM7jXkBRRFLkQOQnxiG6GkzpTQ8jPbgATIGtDlKTsj2gJABUXzhZ1KVRa10mLD4i-MZJfQh2XPp44PSDi61_1ge04LDtxh32ceY9ih5_i2RHvorL2NfIcUXI_Ew8iXQLQijzjbELkdfZK_ccSYZu-Q23nug0t6GumCnXS2J7z8qOfs5_3dy-1D9vT84_H25ilzJeglcyCtUDWqxqFsO93pqsOqVK1uve-sTaKoO9mUsq1EpVpsAZzzjVC-UZXS8px9P86d4_RnRVrMEOhwvB1xWskUdQkpWStI1vJodXEiitiZOYbBxr0RYA60zdYcaZsDbSOESbRT7NvHhrUd0P8L_cWbDNdHA6Y_dwGjIRcSX_QholuMn8L_N7wDZNeVqA</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Williams, Taylor</creator><creator>Salmanian, Ghazaleh</creator><creator>Burns, Morgan</creator><creator>Maldonado, Vitali</creator><creator>Smith, Emma</creator><creator>Porter, Ryan M.</creator><creator>Song, Young Hye</creator><creator>Samsonraj, Rebekah Margaret</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8804-8284</orcidid></search><sort><creationdate>202304</creationdate><title>Versatility of mesenchymal stem cell-derived extracellular vesicles in tissue repair and regenerative applications</title><author>Williams, Taylor ; Salmanian, Ghazaleh ; Burns, Morgan ; Maldonado, Vitali ; Smith, Emma ; Porter, Ryan M. ; Song, Young Hye ; Samsonraj, Rebekah Margaret</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-c03a167e69ce3bf8f85fe546b8bddfaa6b827f3943b5156beb00ccd916d965683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Biotechnology - methods</topic><topic>Biotechnology - standards</topic><topic>Biotechnology - trends</topic><topic>Cellular therapies</topic><topic>Clinical trials</topic><topic>EVs</topic><topic>Extracellular vesicles</topic><topic>Extracellular Vesicles - classification</topic><topic>Extracellular Vesicles - immunology</topic><topic>Extracellular Vesicles - metabolism</topic><topic>Humans</topic><topic>Mesenchymal stem cells</topic><topic>Mesoderm - cytology</topic><topic>Regeneration</topic><topic>Regenerative medicine</topic><topic>Regenerative Medicine - methods</topic><topic>Regenerative Medicine - standards</topic><topic>Regenerative Medicine - trends</topic><topic>Stem Cells - cytology</topic><topic>Tissue repair</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Williams, Taylor</creatorcontrib><creatorcontrib>Salmanian, Ghazaleh</creatorcontrib><creatorcontrib>Burns, Morgan</creatorcontrib><creatorcontrib>Maldonado, Vitali</creatorcontrib><creatorcontrib>Smith, Emma</creatorcontrib><creatorcontrib>Porter, Ryan M.</creatorcontrib><creatorcontrib>Song, Young Hye</creatorcontrib><creatorcontrib>Samsonraj, Rebekah Margaret</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochimie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Williams, Taylor</au><au>Salmanian, Ghazaleh</au><au>Burns, Morgan</au><au>Maldonado, Vitali</au><au>Smith, Emma</au><au>Porter, Ryan M.</au><au>Song, Young Hye</au><au>Samsonraj, Rebekah Margaret</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Versatility of mesenchymal stem cell-derived extracellular vesicles in tissue repair and regenerative applications</atitle><jtitle>Biochimie</jtitle><addtitle>Biochimie</addtitle><date>2023-04</date><risdate>2023</risdate><volume>207</volume><spage>33</spage><epage>48</epage><pages>33-48</pages><issn>0300-9084</issn><eissn>1638-6183</eissn><abstract>Mesenchymal stem/stromal cells (MSCs) are multipotent somatic cells that have been widely explored in the field of regenerative medicine. MSCs possess the ability to secrete soluble factors as well as lipid bound extracellular vesicles (EVs). MSCs have gained increased interest and attention as a result of their therapeutic properties, which are thought to be attributed to their secretome. However, while the use of MSCs as whole cells pose heterogeneity concerns and survival issues post-transplantation, such limitations are absent in cell-free EV-based treatments. EVs derived from MSCs are promising therapeutic agents for a range of clinical conditions and disorders owing to their immunomodulatory, pro-regenerative, anti-inflammatory, and antifibrotic activity. Recent successes with preclinical studies using EVs for repair and regeneration of damaged tissues such as cardiac tissue, lung, liver, pancreas, bone, skin, cornea, and blood diseases are discussed in this review. We also discuss delivery strategies of EVs using biomaterials as delivery vehicles through systemic or local administration. Despite its effectiveness in preclinical investigations, the application of MSC-EV in clinical settings will necessitate careful consideration surrounding issues such as: i) scalability and isolation, ii) biodistribution, iii) targeting specific tissues, iv) quantification and characterization, and v) safety and efficacy of dosage. The future of EVs in regenerative medicine is promising yet still needs further investigation on enhancing the efficacy, scalability, and potency for clinical applications.
•MSC-derived EVs are promising therapeutic agents for several clinical conditions.•Complexity of MSC-EV cargo and effects of culture environments are discussed.•Challenges in MSC-EV manufacturing and possible solutions are addressed.•Biomanufacturing of MSC-EVs requires careful considerations of GMP-compliant processes.</abstract><cop>France</cop><pub>Elsevier B.V</pub><pmid>36427681</pmid><doi>10.1016/j.biochi.2022.11.011</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0001-8804-8284</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0300-9084 |
ispartof | Biochimie, 2023-04, Vol.207, p.33-48 |
issn | 0300-9084 1638-6183 |
language | eng |
recordid | cdi_proquest_miscellaneous_2740515760 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Animals Biotechnology - methods Biotechnology - standards Biotechnology - trends Cellular therapies Clinical trials EVs Extracellular vesicles Extracellular Vesicles - classification Extracellular Vesicles - immunology Extracellular Vesicles - metabolism Humans Mesenchymal stem cells Mesoderm - cytology Regeneration Regenerative medicine Regenerative Medicine - methods Regenerative Medicine - standards Regenerative Medicine - trends Stem Cells - cytology Tissue repair |
title | Versatility of mesenchymal stem cell-derived extracellular vesicles in tissue repair and regenerative applications |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A20%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Versatility%20of%20mesenchymal%20stem%20cell-derived%20extracellular%20vesicles%20in%20tissue%20repair%20and%20regenerative%20applications&rft.jtitle=Biochimie&rft.au=Williams,%20Taylor&rft.date=2023-04&rft.volume=207&rft.spage=33&rft.epage=48&rft.pages=33-48&rft.issn=0300-9084&rft.eissn=1638-6183&rft_id=info:doi/10.1016/j.biochi.2022.11.011&rft_dat=%3Cproquest_cross%3E2740515760%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2740515760&rft_id=info:pmid/36427681&rft_els_id=S0300908422003078&rfr_iscdi=true |